SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

The award provides reputational validation but does not alter Evaxion's clinical or funding timeline. Monitor upcoming clinical data readouts and capital-raising events, as the company's $30M market cap and clinical-stage status imply continued cash needs. No immediate trading catalyst from this release.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.64
T+0 close · Jun 12, 2026 · via day close
Latest settled
−12.91%
T+60 · $3.17
Vs SPY
−16.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $3.64entry
  2. T+1 · 5mo ago −1.10%α −2.86% · $3.60
  3. T+5 · 5mo ago −16.21%α −16.88% · $3.05
  4. T+20 · 4mo ago −12.91%α −14.69% · $3.17
  5. T+60 · 2mo ago −12.91%α −16.18% · $3.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While this is the second Galien recognition in under a year, it is a non-financial, reputational award that does not change the company's clinical or financial trajectory. The filing contains no revenue, EPS, guidance, or other material financial data.

Key Facts

  • Evaxion awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology.
  • This is the second recognition from the Prix Galien Foundation in less than a year (previous award in Dec 2025).
  • Evaxion is a clinical-stage TechBio company with no revenue or financial data disclosed in this release.
  • The award committee comprised 12 experts who evaluated innovation, clinical application, and utility.

Financial Impact

No financial figures disclosed; the award has no immediate revenue or cash impact.

Risk Factors

  • Clinical-stage company with no approved products or disclosed revenue, high cash burn risk.
  • Award has no direct impact on pipeline progression or regulatory milestones.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310899

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026